GRIFOLS SA INH. A EO-,25/ ES0171996087 /
29/07/2024 22:58:56 | Chg. -0.080 | Volume | Bid22:58:56 | Ask22:58:56 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
9.006EUR | -0.88% | - Turnover: - |
9.006Bid Size: - | 9.154Ask Size: - | 7.71 bill.EUR | - | 101.04 |
GlobeNewswire
01/07
Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years
GlobeNewswire
18/06
Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
GlobeNewswire
17/06
Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immu...
GlobeNewswire
18/04
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at ...
GlobeNewswire
04/04
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Scree...
GlobeNewswire
15/11/2023
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous ...